About
Approximately 18.5 million women annually are affected by gynaecological cancer, from which approximately 50% are classified as rare cancers. Delayed diagnosis of patients suffering from rare gynaecological cancers leads to poor outcomes and contributes to a huge socio-economic burden. This field is lagging due to distinct scientific and technological challenges that gynaecological cancer research faces. Currently, the overall efforts for addressing these challenges are fragmented across different European countries and beyond.
GYNOCARE, which is part of a European Collaboration in Science and Technology (COST), aims to address these challenges by creating a unique network between key stakeholders covering five distinct domains (from concept to cure): basic research on rare gynaecological cancer, biobanking, industrial dimension, legal and regulatory requirements for international trials and other research collaborative efforts, and high-quality, international, and innovative clinical trials. The first GYNOCARE Conference is going to be held in Valletta, Malta on the 23rd and 24th May 2022 with the aim to bring together international experts in the field in order to focus on the development of new approaches to improve the diagnosis and treatment of rare gynecological tumours.
